To understand whether IL-17A is also a relevant contributor to CTLA-4 and PD-1 blockade in human melanomas, we used an ex vivo patient-derived tumor fragment (PDTF) model, which has recently demonstrated high predictive capacity for ICI22,23. This evidence concerns the gene IL17A and melanoma.